Lung cancer is one of the most common malignant tumours. Emerging evidences show that lung cancer has become the leading cause of cancer deaths in both males and females worldwide ([@bib33]). Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for ∼85% of all cases of lung cancer. Most NSCLC patients present with advanced tumours that result in poor prognosis. Smoking, respiratory system disease and environmental factors are known risk factors of lung cancer pathogenesis. However, the development of lung cancer is an extremely complicated process in which multiple genes, including genes encoding immune molecules such as B7-H1, B7-H3 and B7-H4, are involved ([@bib11]; [@bib7]; [@bib39]). Therefore, it is urgent to identify the important molecular regulators for lung cancer in order to introduce the novel therapeutic strategies.

The T-cell immunoglobulin domain and mucin domain (TIM) family is a relatively newly discovered group of molecules and has received increasing attention because of its important roles in asthma, allergy and autoimmunity ([@bib22]). In human subjects, the TIM family contains three members: TIM-1, -3 and -4. The TIM proteins belong to type-I cell-surface glycoproteins composed of a signal peptide, an extracellular IgV domain, a mucin-like domain, a transmembrane domain and an intracellular cytoplasmic tail. In contrast to TIM-1 and TIM-3, TIM-4 contains a conserved arginine-glycine-aspartic acid (RGD) motif in IgV domain that is the ligand of integrins. In addition, TIM-4 expression is highly restricted to professional antigen-presenting cells (APCs), suggesting that TIM-4 might exert an important role in regulating immune functions ([@bib24]). It has been found that TIM-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages and plays a dual role in the induction and effector phases of murine arthritis ([@bib40]; [@bib1]). Our published data also show that TIM-4 negatively regulates the function of macrophages ([@bib42]). Though it was originally thought that TIM-4 is not expressed in other immunocytes except APCs, ([@bib19] and [@bib38]) reported the expression of TIM-4 on B1 cells and NKT cells recently. Interestingly, TIM-4 could also be detected in the histiocytic sarcoma, histiocytic and dendritic cell neoplasms as well as Langerhans cell sarcoma ([@bib14]; [@bib21]). In addition, a case report showed that TIM-4 is expressed in parapharyngeal liposarcoma ([@bib20]). These studies suggested the potential role of TIM-4 in tumour development and progression. However, its expression pattern and biological functions in lung cancer remain unclear.

Here we investigated the role of TIM-4 in lung cancer progression. We showed that the expression of TIM-4 in lung cancer tissues was significantly higher than that of adjacent tissues and closely related with histological differentiation of lung carcinoma and lifespan of lung cancer patients. Importantly, TIM-4 overexpression promoted lung cancer cell growth, proliferation and accumulation in S phase that was performed by its RGD motif in IgV domain. Furthermore, we found that TIM-4 interacted with integrin *α*v*β*3 through RGD motif that might account for the effects of TIM-4 in promoting lung cancer progression. This work presented here suggests TIM-4 as a poor prognostic indicator for NSCLC patients.

Materials and methods
=====================

Patient specimens
-----------------

Seventy pairs of NSCLC tumour tissues and adjacent nontumour tissues (at least 3 cm away from the tumour site) were collected from Shandong Provincial Hospital and small-cell lung cancer patients were excluded. None of the patients had received chemotherapy or radiation before resection and all patients were followed-up after operation till 60 months. Informed consent was obtained from all patients before the study was initiated with the approval of the Shandong University Medical Ethics Committee in accordance with the Declaration of Helsinki. All data of the human subjects are summarised in [Table 1](#tbl1){ref-type="table"}. Multiple organ tumour tissue microarray (HOrg-C120PG-01) were purchased from ZuoCheng Bio-tech (Shanghai, China).

Animals
-------

Male BALB/c nude mice (6--8 weeks of age) were purchased from Vital River Laboratory Animal Technology Co. Ltd (Beijing, China). All mice were housed in the animal facilities under the specific pathogen-free conditions. This study has been approved by the Animal Care and Use Committee of Shandong University.

The 5 × 10^7^ A549 cells in 100 *μ*l phosphate-buffered saline (PBS) were subcutaneously injected into the left axillae of the nude mice and these mice were divided into three groups randomly. Tumours were injected with the indicated plasmids (20 *μ*g per 100 *μ*l in PBS) every fourth day for a total of 4 injections after reaching a diameter of 0.5 cm. Meanwhile, tumour size was monitored every other day. Tumour volume was calculated using the following formula: volume=width^2^ × length × 1/2 and growth curve was drawn subsequently. At 14 days after plasmid administration, the mice were killed and the tumours were isolated and weighed. Animal experiments were repeated at least twice. The *TIM-4* mRNA expression in tumour xenografts was detected by real-time PCR. The TIM-4 protein expression and proliferation of tumour cells in tumour tissues were assayed by immunohistochemical staining.

Cell lines and plasmids
-----------------------

The human NSCLC cell lines A549, NCI-H446, NCI-H1975, NCI-H1299, NCI-H358, SPCA-1 and 95-D and human monocyte cell line THP-1 were purchased from the Shanghai Cell Collection (Chinese Academy of Sciences, Shanghai, China). The A549, NCI-H446, NCI-H1299 and SPCA-1 cells were grown in Dulbecco\'s modified Eagle\'s medium (DMEM; GIBCO, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco-BRL, Grand Island, NY, USA), 100 U ml^−1^ penicillin and 100 *μ*g ml^−1^ streptomycin. The NCI-H1975, NCI-H358, 95-D and THP-1 cells were grown in RPMI-1640 (GIBCO) supplemented with 10% FBS (Gibco-BRL), 100 U ml^−1^ penicillin and 100 *μ*g ml^−1^ streptomycin. All the cells were incubated at 37 °C in a 5% CO~2~ humidified incubator.

The recombinant plasmid of full-length *TIM-4* with a carboxy-terminal haemagglutinin (HA) tag (pc3-hT4) was generated by PCR amplification of pcDNA3.0-hTim-4 vector with forward (5′-CCG*GAATTC*GATGTCCAAAGAACCTCTCATT-3′) and reverse (5′-GCTCTAGACTA[AGCGTAGTCTGGTACGTCGTAAGGGTA]{.ul}GAGGGTAAAAAGGCCGTCT-3′) primers, where underlined nucleotides represent the sequence encoding the HA peptide tag fused in frame with TIM-4. Plasmid pc3.0-hT4(m) with RGD motif mutation into alanine was generated by PCR amplification with forward primer (5′-[GCAGCTGCT]{.ul}GTCTCCTTGACCATCTTAAACCCCA-3′) and reverse primer (5′-CGGGATAGTCCCCTGAAGTCTATAT-3′), where underlined nucleotides represent the sequence encoding RGD motif mutated into alanines. pc3-hT4 plasmid was used as template to perform PCR by a KOD-Plus-Mutagenesis Kit (Code No. SMK-101; TOYOBO CO., LTD, Life Science Department, Osaka, Japan).

Transient transfection
----------------------

A549 cells or NCI-H1975 cells were seeded at 1 × 10^5^ per ml in 6-well plates (2 ml per well) and incubated for 12 h. The cells were transiently transfected with plasmid DNA using Lipofectamine 2000 (Invitrogen, Beijing, China) according to the manufacturer\'s instructions.

RT--PCR and quantitative real-time PCR
--------------------------------------

Total RNA was isolated from THP-1 cells, lung cancer cells or tumour xenografts. The RNA quality was assessed spectrophotometrically. Complementary DNA was synthesised using reverse transcription kit (TOYOBO CO., LTD) according to the manufacturer\'s instructions. The mRNA expression levels of *TIM-4* was detected by PCR or real-time PCR. *β-Actin* was selected as the internal control reference gene and normalised values were used to calculate the relative mRNA expression levels. Quantitative real-time PCR reaction was run on CFX96 Real-time PCR system (Bio-Rad, Hercules, CA, USA) using the following conditions: 95 °C for 10 min (an initial denaturation step), followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min (annealing and extension). In addition, melting curve (55--95 °C) was performed at the end of each run. Gene-specific primers were as follows: *TIM-4*, forward (5′-ACAGGACAGATGGATGGAATACCC-3′) and reverse (5′-AGCCTTGTGTTTCTGCG-3′); *β-actin*, forward (5′-GGCATCGTGATGGACTCCG-3′) and reverse (5′-GCTGGAAGGTGGACAGCGA-3′). The relative expression ratios of target gene were calculated considering their amplification efficiencies.

Analysis of cell proliferation and cell cycle
---------------------------------------------

Cell viability was measured using the Cell Counting Kit-8 (CCK-8, CK-04, Dojindo, Tokyo, Japan). Each experiment was repeated 3 times. For *α*v*β*3 blocking assay, 25 *μ*g ml^−1^ of mouse anti-*α*v*β*3 (CBL544, Millipore, Billerica, MA, USA) or mouse IgG were added into A549 cells 6 h after transfection with pc3 or pc3-hT4 plasmid DNA ([@bib17]). For cell cycle analysis, cells were collected 48 h after transfection, stained with propidium iodide (PI, Sigma) for 15 min and further assayed using Beckman Coulter Flow Cytometer (FC500, Beckman-Coulter, Fullerton, CA, USA).

Western blotting
----------------

Cells were lysed by Cell LyticäM (Sigma) and added to gel-loading buffer. After boiling for 10 min, proteins were resolved by SDS--polyacrylamide gel electrophoresis and electroblotted onto a polyvinylidene fluoride membrane (Millipore Co., Billerica, MA, USA). Membranes were blocked with 3% BSA and incubated with indicated antibodies. After washing in PBS containing 0.5% Tween-20, the bound primary antibody was detected with anti-mouse IgG or anti-rabbit IgG (Zhongshan Co., Beijing, China). Following washes, the antibody-bound protein was visualised by enhanced chemiluminescence. Antibodies used are as follows: anti-cyclin A (BS1084, Bioworld Technology, St Louis Park, MN, USA); anti-cyclin B1 (ab32053, Abcam, Cambridge, MA, USA); anti-cyclin D1 (2261-1, Epitomics, Burlingame, CA, USA); anti-PCNA (ab92552, Abcam); mouse-anti-HA monoclonal antibody (TA-04, Zhongshanjinqiao, Beijing, China); rabbit anti-HA polyclonal antibody (51064-2-AP, Proteintech, Chicago, IL, USA); anti-*α*v*β*3 (CBL544, Millipore); and anti-*β*-Actin (TA-09, Zhongshanjinqiao).

Co-immunoprecipitation
----------------------

A549 cells were transfected with pc3-hT4 or pc3-hT4(m) plasmid DNA respectively. After 24 h, the cells were harvested and cell lysates were prepared with RIPA lysis buffer. For co-immunoprecipitation (Co-IP), total cell lysates were incubated overnight with 4 *μ*g of rabbit anti-HA polyclonal antibody (51064-2-AP, Proteintech) or mouse anti-*α*v*β*3 (CBL544, Millipore) antibody and further incubated with protein A/G Sepharose for 4 h. The complex was washed three times with cell lysis buffer, and processed for further western blot analysis.

EdU immunofluorescence staining
-------------------------------

The A549 cells were transfected with plasmid DNA of pc3, pc3-hT4 or pc3-hT4(m). After 94 h, the transfected cells were incubated with EdU for 2 h. Immunofluorescence staining was performed according to standard protocols using Cell-Light EdU Apollo567 In Vitro Imaging Kit (C10310-1, Ribobio, Guangzhou, China), and then the staining results were observed under fluorescence microscope.

Immunohistochemical staining
----------------------------

Immunohistochemical staining was performed according to standard protocols using the following antibodies: anti-TIM-4 (ab47637; Abcam) and anti-Ki-67 (ab15580; Abcam). The TIM-4 and Ki-67 staining were reported separately according to the German semiquantitative scoring system ([@bib18]). Eight fields of ∼1000 cells from each tumour and nontumour section were counted independently by three pathologists.

Statistical analysis
--------------------

GraphPad Prism (GraphPad Software, San Diego, CA, USA) was used for data analysis. The χ^2^ test was used to analyse the statistical correlation between the clinical parameters of lung cancer and the TIM-4 expression levels in tissue sections. Student\'s *t*-test was applied to determine significant differences between groups. Two-way ANOVA was applied to determine significant differences between different treatments at different time points, including the growth curve of A549 cells, NCI-H1975 cells and tumour xenografts in mice. The univariate analysis of survival of NSCLC patients was analysed using the log-rank test. The *P-*values of \<0.05 were considered to be significant.

Results
=======

Enhanced TIM-4 expression in NSCLC tissues is negatively related with the prognosis of lung cancer patients
-----------------------------------------------------------------------------------------------------------

Recently, TIM-4 was found to be expressed in tumours, including histiocytic sarcoma, histiocytic and dendritic cell neoplasms, Langerhans cell sarcoma as well as parapharyngeal liposarcoma ([@bib14]; [@bib21]). In order to clarify the expression pattern of TIM-4 in more kinds of tumours, we examined TIM-4 expression in a variety of tumour tissues using multiple organ tumour tissue microarray by immunohistochemical (IHC) staining. As shown in [Figure 1](#fig1){ref-type="fig"}, the levels of TIM-4 expression in oesophageal cancer, colon cancer, rectal carcinoma, pancreatic cancer, breast cancer and lung cancer tissues were higher than those of the corresponding adjacent tissues respectively, indicating the correlation between TIM-4 and tumours.

To explore the significance of TIM-4 expression in tumour development, we collected NSCLC cancer tissues and paired adjacent tissues from 70 patients who have been followed-up to ensure their survival after tumour resection. We found that TIM-4 expression was detected in both lung squamous cell carcinoma and adenocarcinoma tissues ([Figure 2A](#fig2){ref-type="fig"}). Importantly, we found TIM-4 colocalised with CK-18, a marker of lung epithelial-derived tumour cells ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}) ([@bib29]). Furthermore, TIM-4 expression in lung cancer tissues was significantly higher than that of the adjacent tissues ([Figure 2B](#fig2){ref-type="fig"}). More importantly, higher expression of TIM-4 in lung cancer tissues was negatively correlated with the 5-year overall survival rate of patients ([Figure 2C](#fig2){ref-type="fig"}). We further analysed the correlation of TIM-4 expression levels in NSCLC tissues with patients\' clinical parameters. As shown in [Table 1](#tbl1){ref-type="table"}, TIM-4 levels were significantly negatively correlated with the differentiation of lung cancer. These results suggested that TIM-4 might be involved in NSCLC pathogenesis.

TIM-4 overexpression promotes the growth, proliferation and cell cycle progression of lung cancer cells
-------------------------------------------------------------------------------------------------------

As high expression of TIM-4 was found in NSCLC tissues, its exact role in lung cancer development needs to be identified *in vitro* and *in vivo*. We evaluated the TIM-4 expression levels in selected NSCLC cell line. Compared with THP-1 cells, a relatively low-level transcriptional expression of TIM-4 was detected in these lung cancer cell lines ([Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}).

Our previous data showed that LPS stimulation could induce TIM-4 expression in macrophages ([@bib42]). In systemic lupus erythematosus patients, *TIM-4* mRNA levels in peripheral blood mononuclear cells were positively correlated with TNF-*α* level in serum, indicating that inflammatory factors might upregulate TIM-4 expression ([@bib45]). As bacterial infection and cytokines such as IL-6, TGF-*β* and TNF-*α* in the inflammatory environment of tumours could accelerate the development of cancer ([@bib37]), we observed the effects of LPS and these cytokines on TIM-4 expression. As shown in [Supplementary Figure 2B and C](#sup1){ref-type="supplementary-material"}, stimulation with LPS, IL-6, TGF-*β* and TNF-*α* significantly increased *TIM-4* mRNA expression in A549 and NCI-H1975 cells.

To address the role of TIM-4 in lung cancer development, human TIM-4 eukaryotic expression vector and control vector were transfected into A549 or NCI-H1975 cells respectively and the cell growth was monitored by CCK-8 assay every day. As shown in [Figures 3A and B](#fig3){ref-type="fig"}, the growth rate of TIM-4-transfected cells was significantly higher than that of the control group, whereas knockdown of TIM-4 in A549 cells inhibited the growth of cells ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). At 48 h post transfection, the cell cycle analysis was performed by PI staining and flow cytometry. Compared with the control group, there was an accumulation of cells at S phase in TIM-4-transfected A549 or NCI-H1975 cells ([Figure 3C](#fig3){ref-type="fig"}). Consistently, western blot showed that the expressions of PCNA and cell cycle-related proteins cyclin A, cyclin B1 and cyclin D1 were significantly upregulated by TIM-4 overexpression ([Figure 3D](#fig3){ref-type="fig"}). These data suggested that TIM-4 can promote the growth, proliferation and cell cycle progression of lung cancer cells.

RGD motif is essential for TIM-4 to promote lung cancer cell proliferation and cell cycle progression
-----------------------------------------------------------------------------------------------------

Distinct from other TIM members, there is no tyrosine phosphorylation site in the cytoplasmic region of TIM-4. However, TIM-4 molecule contains one RGD motif in IgV domain. The RGD motif in osteopontin has been shown to be responsible for tumour growth by interacting with integrin av*β*3 ([@bib12]). Thus, we explored the potential role of RGD motif and integrin av*β*3 signalling pathway in TIM-4-promoted lung cancer progression. First, *α*v*β*3 blocking antibody was utilised to verify the possible role of *α*v*β*3 in this process. As shown in [Figure 4A](#fig4){ref-type="fig"}, the effect of TIM-4 on the growth of A549 cells was abolished upon treatment with *α*v*β*3 blocking antibody. Then, the recombinant vector pc3-hT4(m) of human TIM-4 with RGD motif mutation was constructed, and A549 cells were transfected with plasmid DNA of pc3-hT4 or pc3-hT4(m). The Co-IP results showed that integrin *α*v*β*3 could interact with wild-type TIM-4 but not RGD motif-mutated TIM-4 ([Figure 4B](#fig4){ref-type="fig"}).

To elucidate whether the effects of TIM-4 on A549 cell growth, proliferation and cell cycle progression also depend on its RGD motif, A549 cells were transfected with plasmid DNA of pc3, pc3-hT4 or pc3-hT4(m), and CCK-8 assay, cell cycle analysis, western blot and EdU immunofluorescence staining were performed separately at indicated time points post transfection. The results showed that the mutation of RGD motif abolished the effects of TIM-4 on growth, proliferation and cell cycle progression of A549 cells ([Figures 5A--E](#fig5){ref-type="fig"}), suggesting that TIM-4 indeed exert its function in lung cancer cells by interaction with *α*v*β*3 through its RGD domain.

TIM-4 promotes lung cancer growth and proliferation *in vivo*
-------------------------------------------------------------

To clarify the role of TIM-4 in NSCLC *in vivo*, A549 cells were transplanted subcutaneously into BALB/c nude mice. Tumours were injected with pc3, pc3-hT4 or pc3-hT4(m) plasmids as indicated respectively. Tumour volume monitoring and weight analysis showed that the tumour growth rate of mice with pc3-hT4 intratumoural administration was significantly higher than that of the control group, whereas no significant differences were found between mice with pc3-hT4(m) and pc3 injection group ([Figures 6A--C](#fig6){ref-type="fig"}). Real-time PCR ([Figure 6D](#fig6){ref-type="fig"}) and IHC staining ([Figures 7A and B](#fig7){ref-type="fig"}) results showed higher level expression of TIM-4 in tumours from mice with pc3-hT4 and pc3-hT4(m) administration than the control group, indicating successful overexpression of TIM-4 in tumours from these two groups. Ki-67 is a well-known marker for cell proliferation ([@bib36]). In this study, higher expression of Ki-67 was observed in tumours from mice with pc3-hT4 administration, but not in pc3-hT4(m) plasmid DNA administration group ([Figures 7C and D](#fig7){ref-type="fig"}). These results further proved that TIM-4 promoted lung cancer growth and proliferation by its RGD motif.

Discussion
==========

In this study, we describe for the first time an important role of TIM-4 in NSCLC. The augmented expression of TIM-4 in NSCLC cancer tissues is identified. Importantly, higher expression of TIM-4 in lung cancer tissues indicates poor prognosis of patients. Stimulation of LPS and cytokine increases TIM-4 expression in A549 cells. We further show that overexpression of TIM-4 in A549 cells promotes lung cancer cell growth and proliferation both *in vitro* and *in vivo*. Our study strongly suggests that TIM-4 is essential for lung cancer progression. The TIM-4 interacts with integrin *α*v*β*3 through its RGD motif in IgV domain. Furthermore, we provide evidence that TIM-4 promotes lung cancer growth and proliferation depending on RGD domain, suggesting that TIM-4 might be a potential diagnostic marker and therapeutic target of lung carcinoma.

The TIM-4, also named TIMD4, is a cell-surface glycoprotein belonging to TIM family. As a co-stimulator and natural ligand of TIM-1, TIM-4 is involved in specific immune responses required for T-cell activation ([@bib31]; [@bib25]). As a receptor for phosphatidylserine, TIM-4 controls adaptive immunity by mediating the removal of antigen-specific T cells ([@bib2], [@bib3]). Recently, studies have indicated that TIM-4 is also closely associated with tumour tolerance events. It is reported that macrophage-derived TIM-4 may play an important role in tumour tolerance by inducing Tregs in gliomas ([@bib43]). In addition, TIM-4 activates autophagy-mediated degradation of ingested tumours by directly interacting with AMPK*α*1 that leads to impaired CTL responses ([@bib6]). Intriguingly, TIM-4 is recently detected in several kinds of tumour tissues including parapharyngeal liposarcoma. Consistently, we find high expression of TIM-4 in multiple organ tumour tissue microarray and lung cancer tissues in this study. To our surprise, the intensity of TIM-4 transcripts in most of the lung cancer cell lines is low. It is well known that TIM-4 expression is highly restricted to professional APCs, specifically in macrophages and dendritic cells, but not in T cells ([@bib24]; [@bib40]). Our previous studies also show high expression of TIM-4 in macrophages ([@bib42], [@bib41]). We speculate that some factors inhibiting TIM-4 transcripts may exist in the lung cancer cell lines. For example, ZHX2 suppresses TIM-4 transcripts in mouse liver tissues ([@bib16]). In addition, we found that TIM-4 transcript was inducible in macrophages ([@bib42], [@bib41]) as well as lung cancer cells ([Supplementary Figures 2B and C](#sup1){ref-type="supplementary-material"}). Normally, lung cancer cells produce low levels of these cytokines that might contribute to low TIM-4 transcripts in lung cancer cell lines. Interestingly, we demonstrate TIM-4 expression in A549 and NCI-H1975 cells is increased by stimulations with LPS, IL-6, TNF-*α* or TGF-*β*. High levels of LPS or these cytokines exist in local lung cancer tissues ([@bib26]; [@bib23]), indicating that the tumour microenvironments might induce TIM-4 expression, consistent with high expression of TIM-4 in human NSCLC tissues in our study and enhanced expression of TIM-4 on tumour-associated myeloid cells induced by damage-associated molecular patterns from tumour cells ([@bib6]). However, whether TIM-4 expressed in tumour cells is involved in inflammation-mediated tumourigenesis requires to be further investigated.

The major finding of our investigation is the essential role of TIM-4 in the maintenance of lung cancer growth. Strikingly, the use of FG-CC\' siRNA blocking interaction of TIM-1 and TIM-4 is capable of enhancing DC vaccine against gastric cancer ([@bib35]). Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas ([@bib6]). Our group and other researchers have found that the ectopic expression of TIM-3 in tumour cells may be a potentially prognostic marker for patients with NSCLC, prostate cancer, clear cell renal carcinoma or cervical cancer ([@bib46]; [@bib9]; [@bib28]; [@bib44]). However, the role of TIM-4 in tumour cells is undefined. In this study, we confirm that ectopic expression of TIM-4 in NSCLC is a potential marker of poor differentiation and short lifespan of patients. More importantly, overexpression of TIM-4 promotes A549 cell growth and proliferation both *in vitro* and *in vivo*. These data further elucidate the critical role of TIM-4 in NSCLC progression. It has been found that targeting of the TIM-4--AMPK*α*1 interaction constitutes a unique strategy for augmenting antitumour immunity and improving cancer chemotherapy ([@bib5]). Moreover, TIM-4 knockdown in A549 cells inhibits the growth of cells ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). Therefore, targeting TIM-4 might be a hopeful way to eradicate tumour by inhibiting tumour growth and improving immune tolerance cooperatively.

The molecular mechanisms underlying TIM-4-mediated cancer progression remain completely unknown. However, TIM-4 does not mediate direct signalling because of lack of tyrosine phosphorylation site in cytoplasmic tail ([@bib27]). Different from other TIM proteins, TIM-4 contains an RGD motif in its IgV domain that is a hallmark for adhesive proteins ([@bib30]). The RGD sequence is recognised by the integrin family of cell-surface receptors, and RGD peptides preferentially bind to the *α*v*β*3 integrin ([@bib32]; [@bib13]). In this study, the interaction of TIM-4 with *α*v*β*3 is verified by Co-IP assay. Moreover, RGD motif is responsible for the tumourigenic potential of TIM-4 in lung cancer. This finding is consistent with the role of molecules containing RGD motif, such as OPN, Del-1 and MFG-E8, in tumour growth ([@bib4]; [@bib12]; [@bib10]). We have proved that TIM-4 interacts with integrin *α*v*β*3 through its RGD motif in IgV domain. The RGD motif and integrin av*β*3 signalling pathway are responsible for TIM-4-promoted lung cancer progression. However, the interaction of TIM-4 with *α*5*β*1 or other integrins could not be excluded. Very recently, it is reported that TIM-4 utilises integrins as co-receptors to effect phagocytosis of apoptotic cells with the participation of Src-family kinases, FAK, phosphatidylinositol 3,4,5-trisphosphate, nucleotide-exchange factor Vav3 as well as Rho-family GTPases ([@bib15]). Furthermore, RGD-peptide lunasin inhibits Akt-mediated NF-*κ*B pathway by interaction with the *α*v*β*3 integrin ([@bib8]). In addition, depletion of endothelial *β*3-integrin transiently inhibits tumour growth and angiogenesis in mice ([@bib34]). However, whether Src, Akt signalling pathway or vessel formation are involved in TIM-4-mediated lung cancer progression requires to be explored more in depth in the future. Apoptosis signal pathway might also be involved in the process of TIM-4-promoted lung cancer progression as overexpression of TIM-4 inhibits apoptosis of lung cancer cells ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}).

In summary, our results suggest that TIM-4 might be a potential biomarker for NSCLC. We initially demonstrate the underlying molecular mechanisms that TIM-4 promotes growth and proliferation of lung cancer cells by its RGD motif. Our findings provide new insight into the lung cancer pathogenesis mediated by TIM-4 and a novel candidate target for the effective therapy of lung cancer.
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![**Expression of TIM-4 in multiple organ tumour tissue microarray.** Immunohistochemical (IHC) staining was performed to detect TIM-4 expression in multiple organ tumour tissue microarray. Photos of IHC staining are representative of at least 10 similar observations (× 200). The black arrowheads indicate the positive staining of tumour cells shown in brown.](bjc2015323f1){#fig1}

![**Enhanced TIM-4 expression in NSCLC shows poor prognosis.** Immunohistochemical (IHC) staining was performed in 70 cases of NSCLC tissues and pericarcinoma tissues. (**A**) Representative IHC staining images of TIM-4 in NSCLC tissues and pericarcinoma issues (× 200). The negative control indicated that rabbit IgG replaced TIM-4 antibody in the process of IHC staining. (**B**) Staining intensity of TIM-4 in NSCLC tissues was significantly higher than that of the pericarcinoma tissues (*P*\<0.0001). (**C**) The survival rate of lung cancer patients with higher TIM-4 expression was significantly lower than that of the patients with lower TIM-4 expression (*P*\<0.0001).](bjc2015323f2){#fig2}

![**Overexpression of TIM-4 promotes lung cancer cell growth and cell cycle progression.** Cells were set up in 96- or 6-well plates. After grown to 80--90% confluence, A549 or NCI-H1975 cells were transfected with pc3 or pc3-hT4 plasmid DNA. After transfection, CCK-8 assay, cell cycle or protein analysis were performed at indicated time points. (**A**) The cell growth was monitored by CCK-8 assay for 7 days after transfection (\**P*\<0.05, \*\**P*\<0.01). (**B**) The *TIM-4* mRNA was detected by RT--PCR on day 7 after transfection. (**C**) At 48 h after transfection, cell cycle analysis was performed by PI staining and flow cytometry. The represented graph of each group is indicated. (**D**) At 48 h after transfection, the protein expression of PCNA, cyclin A1, B1 and D1 was analysed by western blot. These experiments were repeated at least three times.](bjc2015323f3){#fig3}

![**T-cell immunoglobulin domain and mucin domain 4 (TIM-4) interacts with integrin *α*v*β*3 through its RGD motif.** The A549 cells were seeded in 96- or 6-well plates. After grown to 80--90% confluence, the cells were transfected with pc3, pc3-hT4 or pc3-hT4(m) plasmid DNA separately. After transfection, *α*v*β*3 blocking or Co-IP was performed at indicated time points. (**A**) At 6 h after transfection, 25 *μ*g ml^−1^ of anti-*α*v*β*3 or mouse IgG was added into cells and incubated for 4 days. The cell growth was monitored by CCK-8 assay (\*\*\**P*\<0.001). (**B**) At 48 h after transfection with pc3-hT4 or pc3-hT4(m) plasmid DNA, Co-IP assay was performed. These experiments were repeated at least three times.](bjc2015323f4){#fig4}

![**T-cell immunoglobulin domain and mucin domain 4 (TIM-4) promotes lung cancer cell growth and proliferation by its RGD motif.** The A549 cells were seeded in 96- or 6-well plates. After grown to 80--90% confluence, the cells were transfected with pc3, pc3-hT4 or pc3-hT4(m) plasmid DNA separately. After transfection, CCK-8 assay, EdU staining, cell cycle or protein analysis was performed at indicated time points. (**A**) At 5 days after transfection, the cell growth was monitored by CCK-8 assay (\**P*\<0.05). (**B** and **C**) At 94 h after transfection, cell proliferation was assayed by EdU staining and fluorescence microscope. Scale bars, 100 *μ*[m]{.smallcaps} (\*\**P*\<0.01). (**D**) At 48 h after transfection, the cell cycle was analysed by PI staining and flow cytometry. The represented graph of each group is indicated. (**E**) At 48 h after transfection, the protein expression of PCNA, cyclin A1, B1 and D1 was analysed by western blot.](bjc2015323f5){#fig5}

![**T-cell immunoglobulin domain and mucin domain 4 (TIM-4) promotes lung cancer growth *in vivo.*** The 5 × 10^7^ A549 cells in 100 *μ*l PBS were subcutaneously injected into the left axillae of the nude mice. After reaching a diameter of 0.5 cm, the tumours were injected with plasmid DNA (20 *μ*g per 100 *μ*l in PBS) of pc3, pc3-hT4 or pc3-hT4(m) every fourth day for a total of 4 injections. (**A**) The tumour size was monitored every other day. Tumour volume was calculated using the following formula: volume=width^2^ × length × 1/2 and growth curve was drawn subsequently (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). (**B** and **C**) After 14 days, the mice were killed and the tumours were isolated and weighed. Tumour images were observed (\**P*\<0.05). (**D**) The *TIM-4* mRNA expression in xenograft tumour tissues was examined by real-time PCR (\**P*\<0.05). Animal experiments were repeated twice and at least three mice were included in each group.](bjc2015323f6){#fig6}

![**T-cell immunoglobulin domain and mucin domain 4 (TIM-4) and Ki-67 expression in xenograft tumour tissues.** The A549 cells were subcutaneously injected into the left axillae of the nude mice, and the tumours were injected with plasmid DNA of pc3, pc3-hT4 or pc3-hT4(m) every fourth day for a total of 4 injections. After 14 days, the mice were killed and the tumours tissues fixed in 10% buffered formalin were embedded in paraffin for IHC staining. The control represented the isotype control IgG instead of TIM-4 antibody or Ki-67 antibody in the process of IHC staining. (**A**) The TIM-4 and (**C**) Ki-67 protein expression in xenograft tumour tissues was examined by IHC staining. Photos of IHC staining are representative of at least 10 similar observations (× 200). The expression rate and staining intensity of (**B**) TIM-4 and (**D**) Ki-67 were reported separately according to the German semiquantitative scoring system (\**P*\<0.05).](bjc2015323f7){#fig7}

###### The expression of T-cell immunoglobulin domain and mucin domain 4 (TIM-4) in lung cancer correlates with clinical features

  **Clinical characteristics**    **Cases**   **TIM-4 expression in cancer tissues**   ***P-*****value**            
  ------------------------------ ----------- ---------------------------------------- ------------------- ---- ---- -------
  **Age**                                                                                                           
  ⩾60                                34                         2                              7           11   14   0.684
  \<60                               36                         5                              8           11   12      
  **Sex**                                                                                                           
  Male                               57                         5                             11           21   20   0.158
  Female                             13                         2                              4           1    6       
  **Pathological type**                                                                                             
  Adenocarcinoma                     31                         5                              5           9    12   0.392
  Squamous carcinoma                 39                         2                             10           13   14      
  **Differentiation grade**                                                                                         
  Poor                               24                         1                              2           6    15   0.01
  Well                               46                         6                             13           16   11      
  **Size**                                                                                                          
  \>3 cm                             42                         3                             10           12   17   0.635
  ⩽3 cm                              28                         4                              5           10   9       
  **Lymph node metastasis**                                                                                         
  Yes                                37                         3                              7           12   15   0.92
  No                                 33                         4                              8           10   11      
  **Clinical stage**                                                                                                
  I                                  26                         4                              5           7    9    0.108
  II                                 17                         2                              7           6    2       
  IIIa                               15                         1                              2           5    7       
  IIIb IV                            13                         0                              1           4    8       

[^1]: These authors contributed equally to this work.
